MZE News - Candlesense

Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025

What risks exist if the proof‑of‑mechanism data does not meet expectations or is delayed? How might the Phase 1 results impact analyst consensus estimates and target price for MZE? What market size and pricing assumptions are being used for PKU and CKD indications?

Earnings

25 days ago